Navellier & Associates’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-6,300
| Closed | -$324K | – | 243 |
|
|
2020
Q1 | $324K | Hold |
6,300
| – | – | 0.08% | 172 |
|
|
2019
Q4 | $389K | Sell |
6,300
-744
| -11% | -$45.9K | 0.06% | 208 |
|
|
2019
Q3 | $423K | Sell |
7,044
-2,623
| -27% | -$158K | 0.07% | 188 |
|
|
2019
Q2 | $816K | Sell |
9,667
-970
| -9% | -$81.9K | 0.13% | 146 |
|
|
2019
Q1 | $1.02M | Sell |
10,637
-18,957
| -64% | -$1.81M | 0.16% | 124 |
|
|
2018
Q4 | $2.1M | Buy |
29,594
+3,201
| +12% | +$227K | 0.36% | 68 |
|
|
2018
Q3 | $2.26M | Buy |
26,393
+7,514
| +40% | +$642K | 0.29% | 99 |
|
|
2018
Q2 | $2.19M | Buy |
18,879
+9,227
| +96% | +$1.07M | 0.3% | 99 |
|
|
2018
Q1 | $781K | Buy |
+9,652
| New | +$781K | 0.12% | 154 |
|
|
2015
Q1 | – | Sell |
-28,759
| Closed | -$1.46M | – | 356 |
|
|
2014
Q4 | $1.46M | Buy |
+28,759
| New | +$1.46M | 0.07% | 83 |
|